1. Home
  2. BANL vs CMMB Comparison

BANL vs CMMB Comparison

Compare BANL & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANL

CBL International Limited

N/A

Current Price

$4.60

Market Cap

19.0M

Sector

Energy

ML Signal

N/A

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

N/A

Current Price

$1.31

Market Cap

20.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BANL
CMMB
Founded
2015
2004
Country
Malaysia
Israel
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.0M
20.5M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
BANL
CMMB
Price
$4.60
$1.31
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $15.00
AVG Volume (30 Days)
32.5K
★ 117.2K
Earning Date
08-18-2026
11-19-2026
Dividend Yield
★ 2.22%
N/A
EPS Growth
N/A
★ 101.67
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$40.50
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$1.35
52 Week High
$16.40
$3.55

Technical Indicators

Market Signals
Indicator
BANL
CMMB
Relative Strength Index (RSI) 33.93 25.39
Support Level $0.36 N/A
Resistance Level $5.34 $1.83
Average True Range (ATR) 0.41 0.27
MACD -0.26 -0.17
Stochastic Oscillator 7.69 13.07

Price Performance

Historical Comparison
BANL
CMMB

About BANL CBL International Limited

CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: